Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 13/20 | 0.69 |
| ▸ | MAPT | P10636 | 13/20 | 0.69 |
| ▸ | RAB9A | P51151 | 11/20 | 0.69 |
| ▸ | NPC1 | O15118 | 10/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4734171 | 0.86 | SMN1; SMN2 (0.80) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL4734168 | 0.86 | SMN1; SMN2 (0.80) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL20520189 | 0.86 | SMN1; SMN2 (0.80) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL7449894 | 0.79 | SMN1; SMN2 (0.74) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL17206744 | 0.79 | SMN1; SMN2 (0.74) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL14938579 | 0.77 | SMN1; SMN2 (0.69) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL12113118 | 0.73 | SIRT1 (0.92) | SMN1; SMN2MAPTRAB9ANPC1KMT2A | |
| SCHEMBL12010921 | 0.73 | SIRT1 (0.92) | SMN1; SMN2MAPTRAB9ANPC1KMT2A | |
| SCHEMBL4554299 | 0.72 | SMN1; SMN2 (0.67) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL17206746 | 0.72 | SMN1; SMN2 (0.87) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932300-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-11-03 | — | — | US | disclosed |
| US-9421211-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-08-23 | — | — | US | disclosed |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | NSUN2, EIF2AK2, RNGTT | SMN1; SMN2 850/4885MAPT 1631/4885RAB9A 2490/4885 |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | NSUN2, EIF2AK2, RNGTT | SMN1; SMN2 850/4885MAPT 1631/4885RAB9A 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.